Glenn Tilton - Abbott Laboratories Independent Director


USD 96.76  1.53  1.56%   

Mr. Glenn Fletcher Tilton serves as Independent Director of the Company. Mr. Tilton served as Chairman, President and Chief Executive Officer of UAL Corporationrationration, and Chairman and Chief Executive Officer of United Air Lines, Inc., an air transportation company and wholly owned subsidiary of UAL Corporationrationration, from September 2002 to October 2010. Mr. Tilton also served on the Board of United Continental Holdings, Inc. from 2001 to 2013 and served as its NonExecutive Chairman of the Board from October 2010 to December 2012. Mr. Tilton is also a Director of AbbVie Inc. and Phillips 66. Mr. Tilton also served on the Board of Directors of Lincoln National Corporationrationration from 2002 to 2007, of TXU Corporationrationration from 2005 to 2007, of Corning Incorporated from 2010 to 2012, and as Chairman of the Midwest for JPMorgan Chase Co. and a member of its companywide Executive Committee from June 2011 to June 2014. Having previously served as Chief Executive Officer of UAL Corporationrationration and United Air Lines, Non Executive Chairman of the Board of United Continental Holdings, Inc., Chairman of the Midwest for JPMorgan Chase Co., Chairman, President, and Vice Chairman of Chevron Texaco, and as Interim Chairman of Dynegy, Inc., Mr. Tilton acquired strong management experience overseeing complex multinational businesses operating in highly regulated industries, as well as expertise in finance and capital markets matters.
Age: 72  Director Since 2007      
224 667 6100

Abbott Laboratories Management Efficiency

Abbott Laboratories has Return on Asset of 8.96 % which means that on every $100 spent on asset, it made $8.96 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 24.18 %, implying that it generated $24.18 on every 100 dollars invested. Abbott Laboratories management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 16.84 B in debt with debt to equity (D/E) ratio of 0.46, which is OK given its current industry classification. Abbott Laboratories has a current ratio of 1.97, which is typical for the industry and considered as normal. Debt can assist Abbott Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, Abbott Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abbott Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abbott to invest in growth at high rates of return. When we think about Abbott Laboratories' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives


James RohrGeneral Electric
Robert SwieringaGeneral Electric
James TischGeneral Electric
Douglas WarnerGeneral Electric
Catherine LesjakGeneral Electric
Andrea JungGeneral Electric
Steven MollenkopfGeneral Electric
Paula ReynoldsGeneral Electric
James CashGeneral Electric
Marijn DekkersGeneral Electric
Edward GardenGeneral Electric
Risa LavizzoMoureyGeneral Electric
William BeattieGeneral Electric
Sebastien BazinGeneral Electric
Thomas HortonGeneral Electric
Mary SchapiroGeneral Electric
Rochelle LazarusGeneral Electric
Leslie SeidmanGeneral Electric
Francisco DSouzaGeneral Electric
Susan HockfieldGeneral Electric
James MulvaGeneral Electric
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. Abbott Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 113000 people. Abbott Laboratories (ABT) is traded on New York Stock Exchange in USA and employs 113,000 people.

Abbott Laboratories Leadership Team

Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Samuel Scott, Independent Director
Christopher Scoggins, Senior Vice President - Rapid Diagnostics
Roger Bird, Senior Vice President - U.S. Nutrition
Michael Dale, Senior Vice President - Structural Heart
Sammy Karam, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Heather Mason, Senior Vice President - Abbott Diabetes Care
James Farrell, Independent Director
Phebe Novakovic, Independent Director
JeanYves Pavee, Senior Vice President - Established Pharmaceuticals, Developed Markets
Roxanne Austin, Independent Director
Stephen Fussell, Executive Vice President - Human Resources
Sally Blount, Independent Director
Daniel Starks, Independent Director
Michael Pederson, Senior Vice President - Electrophysiology and Heart Failure
Thomas Frinzi, Senior Vice President - Abbott Medical Optics
Lisa Earnhardt, Executive Vice President - Medical Devices
Alejandro Wellisch, Senior Vice President - Established Pharmaceuticals, Latin America
Robert Alpern, Independent Director
Murthy Simhambhatla, Senior Vice President - Abbott Medical Optics
Glenn Tilton, Independent Director
Darren McDew, Independent Director
Christopher Calamari, Senior Vice President - U.S. Nutrition
Richard Ashley, Executive VP of Corporate Devel.
Michael Rousseau, President - Cardiovascular and Neuromodulation
Charles Brynelsen, Senior Vice President - Abbott Vascular
Hubert Allen, Executive Vice President, General Counsel, Secretary
Charles Foltz, Senior Vice President - Abbott Vascular
Brian Yoor, Chief Financial Officer, Executive Vice President - Finance
Gregory Ahlberg, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Philip Boudreau, Vice President - Finance, Controller
John Ginascol, Executive Vice President - Core Diagnostics
Patricia Gonzalez, Independent Director
Jared Watkin, Senior Vice President - Diabetes Care
Brian Blaser, Executive VP of Diagnostic Products
Scott White, Senior Vice President - International Nutrition
Michael Roman, Independent Director
Deepak Nath, Senior Vice President - Abbott Vascular
Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Mary Moreland, Executive Vice President of Human Resources
Nancy McKinstry, Independent Director
Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Georges Vos, Senior Vice President - Established Pharmaceuticals, Emerging Markets
Thomas Freyman, Executive VP of Fin. and Admin.
Randel Woodgrift, Senior Vice President - CRM
Michelle Kumbier, Independent Director
Eric Fain, Senior Vice President Group President - Cardiovascular and Neuromodulation
John Capek, Executive Vice President - Ventures
Miles White, Chairman, CEO and Chairman of Executive Committee
Robert Ford, President, Chief Executive Officer, Chief Operating Officer, Director
Edward Liddy, Independent Director
John Stratton, Independent Director
Joseph Manning, Senior Vice President - Abbott Nutrition International
William Osborn, Lead Independent Director
Michael Warmuth, Executive Vice President - Established Pharmaceuticals
Louis Morrone, Senior Vice President - Rapid Diagnostics
Robert Funck, Chief Financial Officer, Executive Vice President - Finance
Daniel Salvadori, Senior Vice President - Established Pharmaceuticals, Latin America.
Andrea Wainer, Executive Vice President - Rapid and Molecular Diagnostics

Abbott Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Abbott Laboratories Implied Volatility

Abbott Laboratories' implied volatility exposes the market's sentiment of Abbott Laboratories stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Abbott Laboratories' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Abbott Laboratories stock will not fluctuate a lot when Abbott Laboratories' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Abbott Laboratories in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Abbott Laboratories' short interest history, or implied volatility extrapolated from Abbott Laboratories options trading.

Pair Trading with Abbott Laboratories

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.

Moving together with Abbott Laboratories

+0.63JPMJP Morgan Chase Fiscal Year End 13th of January 2023 PairCorr
+0.82KOCoca-Cola TrendingPairCorr
The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Trending Equities. Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Abbott Stock analysis

When running Abbott Laboratories price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Is Abbott Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abbott Laboratories. If investors know Abbott will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abbott Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abbott Laboratories is measured differently than its book value, which is the value of Abbott that is recorded on the company's balance sheet. Investors also form their own opinion of Abbott Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Abbott Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abbott Laboratories' market value can be influenced by many factors that don't directly affect Abbott Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abbott Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine Abbott Laboratories value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abbott Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.